Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 16/20 | 0.75 |
| ▸ | FLT3 | P36888 | 5/20 | 0.75 |
| ▸ | KIT | P10721 | 3/20 | 0.75 |
| ▸ | AURKA | O14965 | 2/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | MET | P08581 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.75 |
| ▸ | KDR | P35968 | 1/20 | 0.75 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.75 |
| ▸ | MERTK | Q12866 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.75 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121644 | 1.00 | AXL (0.75) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL467745 | 0.94 | AXL (0.71) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121562 | 0.94 | AXL (0.71) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121616 | 0.93 | AXL (0.70) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL2056526 | 0.93 | AXL (0.70) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL2056602 | 0.93 | AXL (0.72) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121553 | 0.93 | AXL (0.72) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL12670653 | 0.92 | AXL (0.78) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL2056512 | 0.91 | AXL (0.72) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121455 | 0.91 | AXL (0.72) | AXLFLT3KITAURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | claimed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | claimed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | claimed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | claimed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | claimed |
| WO-2021214492-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BERGENBIO ASA (NO) | 2021-10-28 | — | — | WO | claimed |
| EP-3804723-A1 | COMBINATION THERAPY | BerGenBio ASA (NO) | 2021-04-14 | — | — | EP | claimed |
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | claimed |
| US-20180153888-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO ASA (NO) | 2018-06-07 | — | — | US | claimed |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| US-20160339021-A1 | USE OF KINASE INHIBTORS | BERGENBIO ASA (NO) | 2016-11-24 | — | — | US | claimed |
| EP-3076966-A2 | USE OF KINASE INHIBITORS | BerGenBio AS (NO) | 2016-10-12 | — | — | EP | claimed |
| US-9079898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | claimed |
| WO-2015082887-A2 | USE OF KINASE INHIBITORS | BERGENBIO AS (NO) | 2015-06-11 | — | — | WO | claimed |
| EP-2387395-B1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2014-10-15 | — | — | EP | claimed |
| EP-2326641-B1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2014-09-03 | — | — | EP | claimed |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2013-12-19 | — | — | US | claimed |
| US-8349838-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | claimed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2024-08-22 | — | — | US | disclosed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| EP-3804723-A1 | COMBINATION THERAPY | BerGenBio ASA (NO) | 2021-04-14 | — | — | EP | disclosed |
| US-20200215064-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO ASA (NO) | 2020-07-09 | — | — | US | disclosed |
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-20180153888-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO ASA (NO) | 2018-06-07 | — | — | US | disclosed |
| US-9801880-B2 | Use of kinase inhibitors | BERGENBIO AS (NO) | 2017-10-31 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20160339021-A1 | USE OF KINASE INHIBTORS | BERGENBIO ASA (NO) | 2016-11-24 | — | — | US | disclosed |
| WO-2016077264-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | DEL MAR PHARMACEUTICALS (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-9173882-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-08-06 | — | — | US | disclosed |
| US-9079898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2326641-B1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8546433-B2 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8349838-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885FLT3 2/4885KIT 444/4885 |
| US-20190336500-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885FLT3 2/4885KIT 444/4885 |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 29/4885KIT 2149/4885 |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 33/4885KIT 2345/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885FLT3 28/4885KIT 2025/4885 |
| US-20150216864-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885FLT3 5/4885KIT 362/4885 |
| US-20130109695-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885FLT3 5/4885KIT 362/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885FLT3 1/4885KIT 1463/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | AXL 3832/4885FLT3 2424/4885KIT 4472/4885 |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885FLT3 2/4885KIT 444/4885 |
| US-20160339021-A1 | USE OF KINASE INHIBTORS | INHA, ERBB2, MAP3K1 | AXL 7/4885FLT3 28/4885KIT 227/4885 |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885FLT3 2/4885KIT 444/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885FLT3 33/4885KIT 890/4885 |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885FLT3 5/4885KIT 362/4885 |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | AXL 1/4885FLT3 2/4885KIT 444/4885 |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 29/4885KIT 2149/4885 |
| US-20180153888-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 33/4885KIT 2345/4885 |
| US-20200215064-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 33/4885KIT 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.